Influenza research hub

A randomized, Phase 1b, single-center, observer-blind, active-controlled study to evaluate the safety, immunogenicity, and immunological mechanisms of one single administration of TETRALITE influenza vaccine at two dose levels of LiteVax Adjuvant, in healthy participants aged 60 years and older and in healthy participants aged 18 to 50 years.

This study is testing a new flu vaccine called TETRALITE in two different strengths, combined with an ingredient called LiteVax. It's looking at how safe it is and how well it helps the body fight off the flu in healthy people aged 18 and over.

An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous (IV) zanamivir in neonates and infants under 6 months of age with confirmed complicated influenza infection.

This study is looking at a medicine called zanamivir, given through a drip, for babies under 6 months old who have severe flu. We want to understand how the medicine works in their bodies and if it helps them get better. It's an early-stage study to see if it's safe and effective for these very young children.

First-in-human Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of the Adjuvanted Universal Influenza Vaccine “fH1/DSP-0546LP” in Healthy Adults

This study is testing a new 'universal flu vaccine' called fH1/DSP-0546LP in healthy adults for the first time. Researchers want to see if it's safe, how well people tolerate it, and if it helps the body build protection against the flu.

Optimizing the time of day of influenza vaccine administration in adults aged 60-85 years: A randomized controlled trial

This study is looking at the best time of day for people aged 60-85 to have their flu jab. We want to see if getting the vaccine at a certain time helps your body create more protection against the flu virus.

Immune responses to influenza vaccinations and viruses among health care personnel

This study looks at how well healthcare workers' bodies respond to flu vaccines and flu viruses. Researchers want to understand their immune system's protection against flu, both from past vaccines and current viruses circulating around.

A Phase 3, Randomized, Observer-blind, Active-controlled, Case-driven Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults ≥50 Years of Age

This study is testing a new mRNA flu vaccine for adults aged 50 and over. Researchers want to see how safe and effective it is compared to a standard flu jab. It aims to protect against the flu and understand how the body reacts to the new vaccine.

Phase 2a, single center, randomized, double-blind, study to evaluate the immunogenicity and safety of one single administration of OVX836 influenza vaccine at two dose levels (180µg or 480μg) given intramuscularly (IM), either as a booster or a primary vaccination in healthy adults previously administered with OVX836, Influvac Tetra® or placebo in the OVX836-002 (EudraCT number: 2019-002939-28) and OVX836-003 (EudraCT number: 2021-002535-39) studies

This study is testing a new flu vaccine called OVX836 in healthy adults. We want to see how safe it is and how well it helps your body fight off the flu at two different dose levels. It’s for people who have had this vaccine or a standard flu jab before.

The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment and prevention of Influenza.

This study is testing a new version of a common flu medicine to see if it works the same way as the original. It's a Phase I trial, meaning it's an early stage of testing involving healthy adults, not people who are ill. The goal is to make sure the new medicine is just as effective.

Taxifolin/Ergothioneine and Immune Biomarkers in Healthy Volunteers (TaxEr)

This study looks at how natural substances, Taxifolin and Ergothioneine, found in foods like apples and mushrooms, might affect our immune system. We want to see if these substances can help improve how our body fights off illness, especially as we get older, by reducing stress on our cells.

A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

This study is testing a new mRNA vaccine (mRNA-1018-H5) for pandemic influenza in healthy adults. Researchers want to see how well it helps the body fight off the flu and if it's safe and causes any side effects. Participants will receive either the vaccine or a dummy shot.

Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model

This study is looking into a new medicine, TRX-100, to see if it can help prevent flu (influenza A). We want to find out if it's safe and effective in healthy adults by giving them the medicine and then a small amount of the flu virus.

GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE

This study looks at how our bodies fight flu after vaccination and infection. We want to understand immune responses in healthy adults (18-55) by comparing a nasal spray flu vaccine with being given the actual flu virus.

A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza

This study is testing a new medicine, CD388, to see if it can prevent flu in people aged 12 and over who are more likely to get seriously ill from the flu. It compares CD388 to a dummy treatment (placebo) to check how well it works and if it's safe.

A Phase 2a randomized, observer-blind, study to evaluate the immunogenicity and safety of mRNA-based multivalent seasonal influenza vaccine candidates in adults 18 years of age and older.

This study is testing new flu vaccines for adults aged 18 and over. It aims to see how well these new vaccines help your body fight the flu and if they are safe to use. We want to find out if they cause any side effects.

Phase IV open-label clinical trial of the immunogenicity and safety of standard dose trivalent inactivated influenza vaccine (Vaxigrip) in a population of people with obesity

This study is looking at how well the standard flu jab (Vaxigrip) works and how safe it is for people who are obese. It will also look at those with type 2 diabetes. We want to see if their bodies make enough protection against the flu after having the vaccine.

A randomized first-in-human, Phase 1, single-center, observer-blind, active-controlled 3-arm study to evaluate the safety, tolerability, and immunogenicity of one single administration of TETRALITE, a novel adjuvanted influenza vaccine, in healthy participants aged 18 to 50 years